Three pathways carry this formula, and all three describe real physiology. The question is not whether the mechanisms exist — they do — but whether one gummy a day delivers enough of anything to move them.
JellyBlue works, in principle, through three pathways. Tongkat ali is proposed to increase free testosterone by displacing it from sex-hormone-binding globulin and supporting Leydig cell function. L-arginine, beetroot nitrate and grape seed proanthocyanidins target nitric oxide production and vascular health. Ashwagandha reduces cortisol via the HPA axis, which indirectly supports testosterone. Horny goat weed’s icariin is claimed to inhibit PDE5. These are ingredient-level mechanisms: no study has measured what this finished gummy does in real men.
Before anything else: the nitrate warning this product needs and does not carry. The official JellyBlue page states that Horny Goat Weed “inhibits the enzyme PDE5 — the same mechanism targeted by prescription performance medications.” If that is accurate, it matters enormously, because PDE5 inhibitors are contraindicated with nitrate medicines such as nitroglycerin and isosorbide — the combination can cause a sudden and dangerous fall in blood pressure. The formula also contains L-Arginine, an established vasodilator, on top of that. If you take nitrates, blood pressure medication or any heart medicine, speak to a pharmacist before ordering. And if fatigue or performance difficulty is new or worsening, that deserves a medical assessment — erectile dysfunction is a recognised early marker of cardiovascular disease, not merely an inconvenience.
Most circulating testosterone is bound to sex-hormone-binding globulin and biologically unavailable. Only the free fraction does the work. Tongkat ali’s proposed mechanism is to increase that free fraction rather than to add hormone from outside — which is genuinely different from testosterone replacement therapy, and a fair distinction for the seller to draw.
The supporting evidence is real. Randomised human trials, including a 12-week study in men aged 30–55, have reported improvements in testosterone markers and self-reported vitality. Proposed secondary mechanisms include direct Leydig cell support and cortisol reduction. Trial quality varies and effect sizes are modest, but this is a legitimate research base rather than a mechanism story.
And critically, the dose is right. Most of those trials used 200 mg daily of a standardised extract, which is exactly what the label carries. Of the seven ingredients, this is the one delivered at a researched amount, and it deserves to be said plainly on a page that is otherwise critical.
Ashwagandha supports the same pathway from a different angle: less cortisol means less suppression of testosterone biosynthesis. That is well-established physiology. The problem is arithmetic rather than biology, and it is covered below.
Actives on the panel — 7
Named on the sales page — 6
Doses published — 3
At a research dose — 1
Below the cited study dose — 2
Finished-product trials — none
Independently verified claims — none
Three of the seven ingredients target the same endpoint, which is a coherent formulation choice. The obstacle is how much of them a single gummy can physically carry.
A direct nitric oxide precursor with a large sports-science literature on blood flow and endothelial function. Researched intakes run 3–6 grams daily, and oral L-arginine also suffers substantial first-pass metabolism. A gummy cannot approach that.
Dietary nitrate converts to nitrite and then nitric oxide, bypassing the arginine pathway entirely. Good evidence — from concentrated, nitrate-standardised juice. Here the amount and the nitrate content are both undisclosed.
Proanthocyanidins with reasonable research on vascular tissue and blood pressure at 150–300 mg. Protective rather than performance-enhancing, and the amount here is not published.
Why this matters more than it sounds. Nitric oxide is the pathway that actually underpins the “performance” part of the marketing. If the L-arginine content is a few hundred milligrams — which is the most a gummy carrying six other actives could plausibly hold — it is roughly a tenth of a researched dose. Beetroot could compensate, but only at a concentration nobody has published. Two undisclosed amounts on the pathway doing most of the promotional work is the weakest part of this formula.
Cortisol and the HPA axis. Chronic stress keeps cortisol elevated, and cortisol directly suppresses testosterone biosynthesis. Ashwagandha’s withanolides modulate the HPA axis and reduce cortisol output. This is the best-evidenced adaptogen effect in the whole category, with randomised placebo-controlled trials reporting reduced cortisol, better sleep and modest strength and testosterone gains.
The catch is the number. Those trials used 300–600 mg of standardised root extract daily. The sales page cites one of them — a 2015 trial reporting a 17% testosterone increase, which used 600 mg. The label carries 100 mg. You cannot cite a study’s result and deliver a sixth of its dose without saying so.
The PDE5 claim. The official page states that icariin, the active in horny goat weed, “inhibits the enzyme PDE5 — the same mechanism targeted by prescription performance medications.” That is a striking thing for a supplement to claim, and it creates an obligation the page does not meet.
PDE5 inhibitors are contraindicated with nitrate medicines. That warning appears on every prescription in the class because the combination can cause profound hypotension. A seller cannot advertise the mechanism as a selling point and omit the contraindication that comes attached to it. In practice, icariin’s PDE5 activity in laboratory assays is far weaker than a prescription drug’s and human evidence at supplement doses is thin — but the person to resolve that is a pharmacist, not a sales page.
“Every active compound at its therapeutically effective dose.” Measured against the label, that holds for one ingredient of seven.
The page also attacks competitors for “underdosed fairy dust ingredients” — while carrying ashwagandha at a sixth and maca at roughly a twentieth of their researched amounts.
Publishing the full panel would fix this instantly. If the undisclosed four are well dosed, saying so is free marketing.
Until then, treat “clinically dosed” as a claim rather than a fact, and ask for the amounts in writing.
The limitation worth repeating. Everything above is ingredient-level science. There is no published clinical trial on the finished JellyBlue gummy — no study measuring what this particular combination, at these particular amounts, does in real men. That is normal for the supplement category and not unique to this product, and the seller’s own disclaimer acknowledges it. But it means the correct mental model is “a formula assembled from ingredients with varying evidence” rather than “a tested product.” Our full review takes a position on whether that justifies the price.
The seller says 2 weeks for early changes, 3–6 weeks for drive and performance, and 8–12 weeks for full effect, recommending at least 90 days. That timeline is broadly consistent with the adaptogen trial literature, which typically ran 8–12 weeks. Note the mismatch with the 60-day refund window and diarise day 50.
Tongkat ali at 200 mg has human trials reporting improvements in testosterone markers, so the mechanism is not invented. But those are modest average effects in study populations, not the transformation the marketing describes, and no trial has tested this finished gummy. If you suspect genuinely low testosterone, a blood test is the only way to know — and hypogonadism has real medical treatment.
Icariin does show PDE5-inhibiting activity in laboratory assays, so the claim has a basis. What is largely missing is human evidence that supplement-level doses produce a clinically meaningful effect. The important point is not whether it works but what the claim implies: if a product is marketed on PDE5 inhibition, the nitrate contraindication belongs on the same page. It is not there.
Not inherently, but they hold less. A capsule can carry 500–800 mg of powder; a gummy has to fit its actives into a gelatin or pectin matrix alongside sweeteners and flavouring, which caps the total active load. For ingredients dosed in grams — L-arginine especially — that ceiling is a real constraint. The trade is adherence against potency, and adherence is worth more than people assume.
Package pricing, shipping and the 60-day guarantee, verified 2026-08-19.
Check the current JellyBlue sale price Compare packages
Redirects to the JellyBlue official website. We may earn a commission at no additional cost to you. Pricing verified 2026-08-19 — confirm your total at checkout.